 |
Jounce Therapeutics
Richard Murray, CEO
USA | Funding: $194.2M (+)
Website: http://jouncetx.com/
We are stepping outside the conventional approach to developing cancer immunotherapies by using our Translational Science Platform to prioritize targets and identify related biomarkers to match the right therapy to the right patients, thereby enabling enriched trial designs, which we believe will lead to shortened development timelines.
Website: http://jouncetx.com/
We are stepping outside the conventional approach to developing cancer immunotherapies by using our Translational Science Platform to prioritize targets and identify related biomarkers to match the right therapy to the right patients, thereby enabling enriched trial designs, which we believe will lead to shortened development timelines.
